Results 121 to 130 of about 49,034 (223)

Pathological features of BRCA-mutated breast cancer in Shenzhen, China: a single-center study. [PDF]

PeerJ
Guan J, Lin S, Liu Y, Zhou W.
europepmc   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

Decisional Conflict About Contralateral Prophylactic Mastectomy in Patients with Breast Cancer with and Without Pathogenic Variants in <i>BRCA</i> Genes. [PDF]

Cancers (Basel)
Sung JH, Katapodi MC, Park SY.
europepmc   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

Deciphering the Effect of Methyl 4‑Hydroxybenzoate on Breast Cancer by Bioinformatics and Experiments. [PDF]

ACS Omega
Mu Y, Zeng X, Yang Z, Duan Y, Su H, Zhu L, Liu H, Xu M, Wang B, Hong W, Meng X, Qian D.   +11 more
europepmc   +1 more source

Pancancer Analysis and the Oncogenic Role of <i>UBTF</i> in Breast Invasive Carcinoma. [PDF]

Int J Mol Sci
He M, Wu Y, Liu S, Hou Y, Sun H, Jin W.
europepmc   +1 more source

BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer. [PDF]

Breast
Guinel T, Lusque A, Mailliez A, Massard V, Jacot W, Guiu S, de la Motte Rouge T, Brain E, Desmoulins I, Arnedos M, Bailleux C, Goncalves A, Levy C, Bachelot T, Bosquet L, Delaloge S, Frénel JS.   +16 more
europepmc   +1 more source

Association of 25-hydroxyvitamin D levels and vitamin D receptor gene polymorphisms with breast cancer risk in Bangladeshi women. [PDF]

Sci Rep
Akter R, Islam MS, Mosaddek ASM, Akhtar MW, Afrose A, Haque MA, Azam F, Sharmin S, Hasan R, Hossain MM, Bhowmick RK, Asaduzzaman M.   +11 more
europepmc   +1 more source

MRPS28 serves as a biomarker of diagnostic, prognostic, and immune modulation in pan-cancer and promotes breast cancer malignant phenotypes. [PDF]

Front Immunol
Guo X, Wang S, Lu Y, Cai R, Luo Z, Hu J, Xue F, Niu H.   +7 more
europepmc   +1 more source

Identification and validation of a novel estrogen-related model for breast cancer to predict the prognosis. [PDF]

Transl Cancer Res
Xia M, Dong S, Cao J, Wang J, Wang C.
europepmc   +1 more source